MAT SOW Questions.pdf

MAT SOW Questions

Section of the SOW: 4.1.2 OTP Licensure/Certification. The Contractor must provide medication-assisted treatment in an opioid treatment program (OTP) that is both certified and accredited; licensed by the state in which they operate; and registered with the local DEA office.

Question 1: Unless required by the State, this would not pertain to us as we are not dispensing medication and are not providing Methadone. Is this your understanding?

Response: This contract is to provide Medication Assisted Treatment (MAT) by telehealth services

(TeleMAT) and will only include the use of buprenorphine products and naltrexone to treat offenders with opioid used disorders.

Section of the SOW: 4.1.5 Record Keeping Requirements. The Contractor must keep records and inventories of all controlled substances dispensed, including approved buprenorphine products, under the Persons Required to Keep Records and File Reports, 21 Code of Federal Regulations (CFR) PART

1304.03.

Question 2: Unless the model will change, we will not be dispensing medications. Would copies of prescriptions in client files suffice for tracking?

Response: The Persons Required to Keep Records and File Reports, 21 Code of Federal Regulations

(CFR) PART 1304.03 is a specific federal record keeping requirement that applies to buprenorphine treatment. Practitioners must keep records and inventories of all controlled substances dispensed, including approved buprenorphine products. Please refer to the Code of Federal Regulation Part

1304.03 for proper compliance.

Section of the SOW: 4.1.12 Diversion. Diversion is defined as the unauthorized rerouting of prescription medication to someone other than for whom it was intended, including sharing or selling a prescribed medication. The Contractor must implement procedures for prevention of diversion, such as using buprenorphine/naloxone combination products when cost is not an issue and clinically indicated;

counsel offenders on safe storage of, and non-sharing of medications; counsel offenders on taking medication as instructed and explicitly explain definitions of diversion and misuse; check PDMP for new referrals and check regularly thereafter; prescribe a therapeutic dose tailored to offender’s needs; and ensure offender understands treatment agreement and prescription policies.

Question 3: As part of our Diversion Program, for those living at the Residential Reentry Centers, are we able to have the staff pick up the prescriptions? I ask for two reasons, first, many of our clients do not have identification when they come to us and the pharmacies will not accept their prison IDs. They are not able to pick up their MAT medication on their own. This creates a scenario where family members or friends have to pick up the medications if the RRC will not which I think is problematic. 2. Given the potential for misuse of MAT medications, most of our RRCs pick them and log them into the facility prior to making them available to our clients. This, however, is not the case at all RRCs, but I think it should

be. Do they have policies on the RRM side in their SOW’s regarding the management of controlled medications?

Response: Residential Reentry Centers (RRCs) have written policy and procedures regarding the control and distribution of an offender's prescribed medication. RRCs ensure offender medications are properly and safely stored with access to their medication provided by RRC staff.

Section of the SOW: 4.1.17 Evidence-Based Behavioral Counseling/Therapy. A critical element of MAT is participation in behavioral treatment to modify attitudes and behaviors related to substance use and to increase healthy life skills. Offenders receiving MAT for OUD are at increased risk for relapse to opioid use and interventions should target reducing relapse risk factors. The Contractor shall incorporate, but is not required to provide, behavioral counseling in an offender’s MAT program, e.g., cognitive-behavioral therapies, relapse prevention, and motivational interviewing. The Contractor shall only provide behavioral counseling sessions as authorized on the Treatment Referral and Authorization.

Question 4: I did not see any line items for counseling. Will the contracted CTS providers be providing all of the substance abuse treatment? Does the Bureau have an expectation that we would provide the treatment if a provider was not available / failing to perform?

Response: This contract will not be providing any counseling. Counseling services will be provided by the Community Treatment Services contractor at the offender’s location.

Section of the SOW: 5.4.1. MAT - Administration of Methadone (CLIN 4010): Methadone is typically given in liquid form as a daily dose taken under observation. Services for MAT which prescribe methadone for an opioid use disorder are only billable when dispensed by an OTP licensed by the state and certified by SAMHSA, in accordance with state and federal regulations. Price is per daily administration and/or dispensing.

Question 5: I wanted to please confirm that this solicitation does not include Methadone.

Response: This contract is to provide TeleMAT services utilizing buprenorphine products and naltrexone. It does not include the use of methadone.